Latest News and Press Releases

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Uveitis - Global Clinical Trials Review, 2025" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2...

Dublin, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The "Achromatopsia Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Achromatopsia Market is experiencing...

Dublin, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The "Artificial Iris Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Artificial Iris Market has shown...

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) --...

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric Viret, Ph.D., as the company’s Chief...

ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritisPrivosegtor is advancing...

Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on...